Industrialization of Drug Discovery : From Target Selection Through Lead Optimization book cover
1st Edition

Industrialization of Drug Discovery
From Target Selection Through Lead Optimization

Edited By

Ph.D. Handen

  • This format cannot be shipped to your selected country.
ISBN 9780824723910
Published May 26, 2005 by CRC Press
328 Pages 39 B/W Illustrations

FREE Standard Shipping

Prices & shipping based on shipping country


Book Description

The drug discovery and development process is getting longer, more expensive, and no better. The industry suffers from the same clinical attrition and safety-related market withdrawal rates today as it did 20 years ago. Industrialization of Drug Discovery: From Target Selection Through Lead Optimization scrutinizes these problems in detail, contrasting the promise of technology and industrialization with the challenges of using the tools available to their best advantage. The book explores early successes, examines the current state of the art, and provides a strategic analysis of the issues currently facing drug discovery.

Introducing the historical background and current status of the industry, the book delineates the basic tenets underlying modern drug discovery, how they have evolved, and their use in various approaches and strategies. It examines, in detail, the regulations, requirements, guidelines, and draft documents that guide so many FDA actions. The editor devotes the remainder of the discussion to industrialization, compound and knowledge management functions, the drug screening process, collaboration, and finally, ethical issues.

Drawing on real-life, from-the-trenches examples, the book elucidates a new approach to drug discovery and development. This modern-day, back-to-basics approach includes three steps: understand the science, unravel the story, and then intelligently apply the technology, bringing to bear the entire armamentarium of industrialization techniques, not just automation, to the discovery process. Using these steps, you can meet the goals of more specific targets, more selective compounds, and decreased cycle times. In effect, you can look for a bigger needle in a smaller haystack.

Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.

Table of Contents

Drug Discovery in the Modern Age: How We Got Here and Where Do We Go?. The Regulatory Age. Industrialization Not Automation. Compound Management. High Throughput Screening. Parallel Lead Optimization. Knowledge Management. ROI – How to Measure It? How to Get It?. Collaboration in a Virtual and Global Environment. From Genome to Drug: Ethical Issues.

View More



Jeffrey S. Handen, Ph.D.


“The book comprises of 10 well-defined chapters. Detailed discussion on historical background to drug discovery in modern age consists of basic concepts, how they have evolved and various approaches and strategies in modern drug discovery. … The book provides a very good review on all aspects of industrialization of drug discovery. … the book is of particular interest since it gives a systematic and in depth account of related topics to transform research into industrialization. This is a very good book of relevance to anyone interested in drug discovery and more, so for all personnel working in drug discovery.”
—K. S. Laddha, Reader in Pharmacognosy, University Institute of Chemical Technology, Mumbai, in Chemical Industry Digest, February 2007

"Chapter 4, the best part of the book, is an extensive and excellent discussion of aspects of compound- library management. The authors of this chapter have considered all basic aspects of this important component of drug discovery . . . well written with extensive references."

– Robert Goodnow, Hoffmann-LaRoche, in ChemMedChem, 2006, No. 3